Secondary myeloid neoplasms (sMNs) remain the most serious long-term complications in patients with aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH). However, sMNs lack specific predictors, dedicated surveillance measures, and early therapeutic interventions.
Gurnari, C., Pagliuca, S., Prata, P.h., Galimard, J., Catto, L., Larcher, L., et al. (2023). Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria. JOURNAL OF CLINICAL ONCOLOGY, 41(1), 132-142 [10.1200/JCO.22.00710].
Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria
Gurnari, Carmelo;Voso, Maria Teresa;
2023-09-02
Abstract
Secondary myeloid neoplasms (sMNs) remain the most serious long-term complications in patients with aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH). However, sMNs lack specific predictors, dedicated surveillance measures, and early therapeutic interventions.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
jco.22.00710.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
577.94 kB
Formato
Adobe PDF
|
577.94 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
